Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Change in Cash: 2018-2025

Historic Change in Cash for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to -$73.1 million.

  • Bicycle Therapeutics' Change in Cash fell 3.72% to -$73.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.5 million, marking a year-over-year decrease of 176.08%. This contributed to the annual value of $353.1 million for FY2024, which is 88.00% up from last year.
  • As of Q3 2025, Bicycle Therapeutics' Change in Cash stood at -$73.1 million, which was down 2.24% from -$71.5 million recorded in Q2 2025.
  • Bicycle Therapeutics' Change in Cash's 5-year high stood at $504.4 million during Q2 2024, with a 5-year trough of -$86.5 million in Q1 2025.
  • Its 3-year average for Change in Cash is $28.2 million, with a median of -$45.7 million in 2023.
  • Its Change in Cash has fluctuated over the past 5 years, first tumbled by 1,319.67% in 2022, then spiked by 2,154.88% in 2023.
  • Quarterly analysis of 5 years shows Bicycle Therapeutics' Change in Cash stood at $179.2 million in 2021, then tumbled by 112.46% to -$22.3 million in 2022, then tumbled by 104.63% to -$45.7 million in 2023, then spiked by 75.16% to -$11.3 million in 2024, then declined by 3.72% to -$73.1 million in 2025.
  • Its last three reported values are -$73.1 million in Q3 2025, -$71.5 million for Q2 2025, and -$86.5 million during Q1 2025.